Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.

BACKGROUND Although medical practice guidelines exist, there have been no large-scale studies assessing the relationship between initial antimicrobial therapy and medical outcomes for patients hospitalized with pneumonia. OBJECTIVE To determine the associations between initial antimicrobial therapy and 30-day mortality for these patients. METHODS Hospital records for 12945 Medicare inpatients (> or = 65 years of age) with pneumonia were reviewed. Associations between initial antimicrobial regimens and 30-day mortality were assessed with Cox proportional hazards models, adjusting for baseline differences in patient characteristics, illness severity, and processes of care. Comparisons were made with patients treated with a non-pseudomonal third-generation cephalosporin alone (the reference group). RESULTS Initial treatment with a second-generation cephalosporin plus macrolide (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.52-0.96), a non-pseudomonal third-generation cephalosporin plus macrolide (HR, 0.74; 95% CI, 0.60-0.92), or a fluoroquinolone alone (HR, 0.64; 95% CI, 0.43-0.94) was independently associated with lower 30-day mortality. Adjusted mortality among patients initially treated with these 3 regimens became significantly lower than that in the reference group beginning 2, 3, and 7 days, respectively, after hospital admission. Use of a beta-lactam/beta-lactamase inhibitor plus macrolide (HR, 1.77; 95% CI, 1.28-2.46) and an aminoglycoside plus another agent (HR, 1.21; 95% CI, 1.02-1.43) were associated with an increased 30-day mortality. CONCLUSIONS In this study of primarily community-dwelling elderly patients hospitalized with pneumonia, 3 initial empiric antimicrobial regimens were independently associated with a lower 30-day mortality. The more widespread use of these antimicrobial regimens is likely to improve the medical outcomes for elderly patients with pneumonia.

[1]  J. Bartlett,et al.  Community-acquired pneumonia. , 2013, The New England journal of medicine.

[2]  E. Graves,et al.  Advance Data from Vital and Health Statistics of the Centers for Disease Control and Prevention/national Center for Health Statistics , 1994 .

[3]  W. Kapoor,et al.  New and Emerging Etiologies for Community‐Acquired Pneumonia with Implications for Therapy: A Prospective Multicenter Study of 359 Cases , 1990, Medicine.

[4]  P. F. Adams,et al.  Current estimates from the National Health Interview Survey, 1994. , 1995, Vital and health statistics. Series 10, Data from the National Health Survey.

[5]  M. Fine,et al.  Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. , 1998, The American journal of medicine.

[6]  R. Leone,et al.  Antibiotic Prescribing Patterns in Italian Hospital Inpatients with Pneumonia, Chronic Obstructive Pulmonary Disease, and Urinary Tract Infections , 1993, The Annals of pharmacotherapy.

[7]  Inger,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[8]  M. Hammerschlag.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae , 1994, Antimicrobial Agents and Chemotherapy.

[9]  F. Goldstein,et al.  Trends in bacterial resistance to fluoroquinolones. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Niederman,et al.  Guidelines for the initial management of community-acquired pneumonia: savory recipe or cookbook for disaster? , 1995, American journal of respiratory and critical care medicine.

[11]  M. Fine,et al.  Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.

[12]  E. Hook,et al.  Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. , 1983, JAMA.

[13]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .

[14]  M. Kolczak,et al.  Incidence of Community-Acquired Pneumonia Requiring Hospitalization Results of a Population-Based Active Surveillance Study in Ohio , 1997 .

[15]  R. Garibaldi,et al.  Epidemiology of community-acquired respiratory tract infections in adults , 1985, The American Journal of Medicine.

[16]  M. Fine,et al.  Prognosis of patients hospitalized with community-acquired pneumonia. , 1990, The American journal of medicine.

[17]  J. Bartlett,et al.  GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA Community-Acquired Pneumonia in Adults: Guidelines for Management , 1998 .

[18]  R. Gaynes,et al.  Ciprofloxacin Resistance Among Nosocomial Pseudomonas aeruginosa and staphylococcus aureus in the United States , 1995, Infection Control & Hospital Epidemiology.

[19]  M. Fine,et al.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. , 1996, JAMA.

[20]  Graves Ej,et al.  1994 summary: National Hospital Discharge Survey. , 1996, Advance data.

[21]  R. Jones.  Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity. , 1992, The American journal of medicine.

[22]  M. Kolczak,et al.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. , 1997, Archives of internal medicine.

[23]  J. Hindler,et al.  Comparative activity of twelve beta-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: effects of serum protein and capsular material on potency and spectrum as measured by reference tests. , 1996, Diagnostic microbiology and infectious disease.

[24]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[25]  R. Rodríguez-Roisín,et al.  Severe community-acquired pneumonia. Epidemiology and prognostic factors. , 1991, The American review of respiratory disease.

[26]  A. Cantor,et al.  Extending SAS Survival Analysis Techniques for Medical Research , 1997 .

[27]  D. Taylor-Robinson.  Infections due to species of Mycoplasma and Ureaplasma: an update. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  R. Breiman,et al.  Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. , 1996, JAMA.

[29]  D J Barnes.  Microbial etiology of acute pneumonia in hospitalized patients. , 1993, Chest.

[30]  W. Dankner.  The Continued Emergence of Drug-Resistant Streptococcus pneumoniae in the United States: An Update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System , 1997 .

[31]  B. Prosser,et al.  Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates. , 1995, Diagnostic microbiology and infectious disease.

[32]  F. L. Force.  Community-acquired lower respiratory tract infections: Prevention and cost-control strategies , 1985 .

[33]  V L Yu,et al.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .

[34]  C. Schoenborn,et al.  Current estimates from the National Health Interview Survey. , 1988, Vital and health statistics. Series 10, Data from the National Health Survey.

[35]  R. Jones,et al.  The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance. , 1993, Diagnostic microbiology and infectious disease.

[36]  R. Peeling,et al.  Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. , 1997, JAMA.

[37]  T. Marrie,et al.  Community-acquired pneumonia requiring hospitalization: 5-year prospective study. , 1989, Reviews of infectious diseases.

[38]  J. R. Parsons,et al.  Bacteremia With Streptococcus pneumoniae: Implications for Therapy and Prevention , 1996 .

[39]  M. Cetron,et al.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. , 1996, The Journal of infectious diseases.

[40]  M. Fine,et al.  Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. , 1993, The American journal of medicine.

[41]  G. Doern,et al.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study , 1996, Antimicrobial agents and chemotherapy.